Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19366854 | 1.00 | MAPT (0.43) | MAPTSLC7A5PSMB5TSHRGLS | |
| SCHEMBL22747544 | 0.90 | MAPT (0.37) | MAPTSLC7A5PSMB5GLS | |
| SCHEMBL15569263 | 0.86 | MAPT (0.42) | MAPTDPP4DPP8DPP9DPP7 | |
| SCHEMBL1204246 | 0.84 | TSHR (0.37) | MAPTSLC7A5PSMB5TSHRGLS | |
| SCHEMBL13030929 | 0.83 | SLC7A5 (0.39) | SLC7A5PSMB5TSHRGLSDPP4 | |
| SCHEMBL13030928 | 0.83 | SLC7A5 (0.39) | SLC7A5PSMB5TSHRGLSDPP4 | |
| SCHEMBL19209713 | 0.83 | MAPT (0.46) | MAPTTSHRFFAR1ALOX15 | |
| SCHEMBL7890746 | 0.82 | SLC7A5 (0.38) | MAPTSLC7A5PSMB5TSHRGLS | |
| SCHEMBL10363386 | 0.80 | TSHR (0.50) | SLC7A5PSMB5TSHRGLSDPP4 | |
| SCHEMBL1515227 | 0.80 | TSHR (0.50) | SLC7A5PSMB5TSHRGLSDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | MAPT 4568/4885SLC7A5 3290/4885PSMB5 3546/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | MAPT 4568/4885SLC7A5 3290/4885PSMB5 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.